American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: http://www.sciepub.com/journal/ajmcr Editor-in-chief: Samy, I. McFarlane
Open Access
Journal Browser
Go
American Journal of Medical Case Reports. 2015, 3(9), 301-303
DOI: 10.12691/ajmcr-3-9-10
Open AccessCase Report

Myocardial Infarction in a Splenectomized Patient with Immune Trombocytopenia

Ilknur NIZAM1, , Mehmet Ali Erkurt2, Ilhami Berber2, Emin Kaya2, Irfan Kuku2 and Mustafa Koroglu3

1Department of Internal Medicine, Faculty of Medicine, Inonu University, Malatya, TURKEY

2Turgut Ozal Medical Center

3Karabuk Education and Research Hospital

Pub. Date: August 28, 2015

Cite this paper:
Ilknur NIZAM, Mehmet Ali Erkurt, Ilhami Berber, Emin Kaya, Irfan Kuku and Mustafa Koroglu. Myocardial Infarction in a Splenectomized Patient with Immune Trombocytopenia. American Journal of Medical Case Reports. 2015; 3(9):301-303. doi: 10.12691/ajmcr-3-9-10

Abstract

Immune trombocytopenia is an autoimmune disease characterised by abnormal platelet destruction. Corticosteroids and intravenous immune globulin are main first line treatment options. Splenectomy is a preferred second line treatment option for unresponsive patients at many centers. Secondary thrombocytosis is a possible complication awaiting this group of patients after splenectomy. Here, we present a case of myocardial infarction at a patient who had undergone splenectomy for ITP, which is a rare event seen with secondary thrombocytosis due to splenectomy.

Keywords:
immune thrombocytopenia splenectomy myocardial infarction

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

Figure of 1

References:

[1]  Jernås M; Nookaew I; Wadenvik H; Olsson B Differential expression of T-cell genes in blood and bone marrow between ITP patients and controls. Thromb Haemos. 2013 Jan; 109(1):112-7.
 
[2]  Olsson B, Andersson PO, Jernås M, et al. T-cell mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003; 9(9): 1123-1124.
 
[3]  Bussel JB, Lee CS, Seery C, Imahiyerobo AA, Thompson MV, Catellier D, Turenne IG, Patel VL, Basciano PA, Elstrom RL, Ghanima W. Rituximab and 3 dexamethasone cycles provide responses similar to splenectomy in women and those with Immune Thrombocytopenia less than 2 years duration. Haematologica. 2014 Apr 18.
 
[4]  Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115(2): 168-86.
 
[5]  Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001; 97(9): 2549-54.
 
[6]  Arnold DM, Kelton JG. Current options for the treatment of idiopathic thrombocytopenic purpura. Semin Hematol. 2007 Oct; 44(4 Suppl 5): S12-23.
 
[7]  Cheng G. Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile. Ther Adv Hematol. Jun 2012; 3(3): 155-164.
 
[8]  Schwartz J, Leber MD, Gillis S, Giunta A, Eldor A, Bussel JB. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol. 2003 Feb; 72(2): 94-8.
 
[9]  Kojouri K, Vesely SK, Terrell DR, George JN. Review Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004 Nov 1; 104(9): 2623-34.
 
[10]  Norgaard M. Thrombosis in patients with primary chronic immune thrombocytopenia. Thromb Res 2012;130(Suppl. 1):S74-75.
 
[11]  Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomised, double-blind, placebo-controlled trial. Lancet 2009;373:641–648.
 
[12]  Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357: 2237-2247.
 
[13]  Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, Jeffers L, McHutchison J, Chen PJ, Han KH, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012; 367: 716-724.
 
[14]  Kim WH, Park JB, Jung CW, Kim GS. Rebalanced hemostasis in patients with idiopathic thrombocytopenic purpura. Platelets 2014.
 
[15]  Yagmur J, Cansel M, Acikgoz N, Yagmur M, Eyupkoca F, Ermis N, Akturk E. Multivessel Coronary Thrombosis in a Patient with Idiopathic Thrombocytopenic Purpura. Tex Heart Inst J. 2012; 39(6): 881-883.
 
[16]  Gracia MC, Cebollero IC, Lezcano JS, Osuna GG, Miguel JA, Peralta LP. Invasive treatment performed for acute myocardial infarction in a patient with immune thrombocytopenic purpura. Int J Cardiol 2008;127(3):e183–5
 
[17]  Yildiz A, Coskun U, Batukan OE, Keskin K. Primary percutaneous coronary intervention for acute myocardial infarction in a young female with idiopathic thrombocytopenic purpura: a case report and review. Case Report Med 2010; 2010: 854682.
 
[18]  Aydogan T, Kanbay M, Alici O, Kosar A. Incidence and etiology of thrombocytosis in an adult Turkish population. Platelets. 2006 Aug; 17(5): 328-31.
 
[19]  Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med. 1999 Mar; 245(3): 295-300.